Summer Street Still on Sidelines Following Isis Pharma's (ISIS) ISIS-FXIRx Update; Maintains at 'Neutral'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. MRNA
2. KEYS
3. KLAR
4. PANW
5. HD
6. DVLT
7. LOW
8. MRK
9. PGR
10. EPM

Go back to Summer Street Still on Sidelines Following Isis Pharma's (ISIS) ISIS-FXIRx Update; Maintains at 'Neutral'

ISIS Pharmaceuticals (ISIS) May Have Best Pipeline in Biotech - Piper Jaffray

May 23, 2014 7:49 AM EDT

Piper Jaffray analyst Joshua Schimmer, MD reiterated an Overweight rating and $42 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) following yesterday's ISIS R&D day saying the company may have the best pipeline in biotech.

We attended yesterday's ISIS R&D day. In... More

ISIS Pharmaceuticals (ISIS) Top-Line ISIS-FXI Data Viewed as Encouraging - Deutsche Bank

May 22, 2014 8:20 AM EDT

Deutsche Bank maintained a Buy rating on ISIS Pharmaceuticals (NASDAQ: ISIS) with a price target of $60. Analyst Alethia Young said top-line data from ISIS-FXI looks encouraging.

"Isis presented top-line data for ISIS-FXI vs. heparin in patients that had... More

Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Top-Line Data from ISIS-FXIRx in VTE

May 22, 2014 7:09 AM EDT

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXIRx inhibits the production of... More